HC Wainwright Expects Increased Earnings for FocalTherics

FocalTherics (NASDAQ:FOCL) – Investment analysts at HC Wainwright upped their FY2026 earnings estimates for FocalTherics in a report released on Friday, November 6th. HC Wainwright analyst S. Ramakanth now forecasts that the company will post earnings of ($0.71) per share for the year, up from their prior forecast of ($0.82). HC Wainwright currently has a “Buy” rating and a $10.00 target price on the stock. The consensus estimate for FocalTherics’ current full-year earnings is ($0.82) per share. HC Wainwright also issued estimates for FocalTherics’ Q4 2026 earnings at ($0.16) EPS, Q1 2027 earnings at ($0.14) EPS, Q2 2027 earnings at ($0.10) EPS, Q3 2027 earnings at ($0.14) EPS, Q4 2027 earnings at ($0.05) EPS, FY2027 earnings at ($0.43) EPS, FY2029 earnings at $0.03 EPS and FY2030 earnings at $0.21 EPS.

A number of other research analysts have also recently weighed in on FOCL. Weiss Ratings reiterated a “sell (d-)” rating on shares of FocalTherics in a report on Monday, August 17th. Wall Street Zen upgraded FocalTherics from a “sell” rating to a “hold” rating in a research note on Saturday. Piper Sandler restated a “neutral” rating and set a $4.00 price target on shares of FocalTherics in a research note on Friday, August 14th. Finally, Mizuho started coverage on FocalTherics in a report on Friday, July 17th. They issued an “outperform” rating and a $15.00 price objective on the stock. One research analyst has rated the stock with a Strong Buy rating, one has given a Buy rating, one has assigned a Hold rating and one has issued a Sell rating to the company. Based on data from MarketBeat, the stock currently has an average rating of “Moderate Buy” and a consensus price target of $9.67.

FocalTherics Stock Up 6.0%

Shares of FOCL stock opened at $3.52 on Tuesday. The company has a quick ratio of 1.38, a current ratio of 1.60 and a debt-to-equity ratio of 1.79. FocalTherics has a one year low of $1.82 and a one year high of $6.40. The stock’s 50 day moving average is $4.21.

FocalTherics (NASDAQ:FOCL) last released its earnings results on Thursday, November 5th. The company reported ($0.10) EPS for the quarter, topping the consensus estimate of ($0.18) by $0.08. The firm had revenue of $9.83 million during the quarter. FocalTherics had a negative net margin of 56.26% and a negative return on equity of 248.00%.

Institutional Inflows and Outflows

An institutional investor recently raised its position in FocalTherics stock. Rock Springs Capital Management LP boosted its position in shares of FocalTherics (NASDAQ:FOCL) by 7.1% in the first quarter, according to the company in its most recent 13F filing with the Securities and Exchange Commission. The institutional investor owned 1,378,000 shares of the company’s stock after purchasing an additional 91,500 shares during the period. Rock Springs Capital Management LP owned approximately 3.68% of FocalTherics worth $5,126,000 at the end of the most recent reporting period. Institutional investors own 62.74% of the company’s stock.

Insider Activity

In related news, Director Joshua Levine purchased 10,000 shares of FocalTherics stock in a transaction that occurred on Friday, August 14th. The shares were purchased at an average cost of $4.75 per share, with a total value of $47,500.00. Following the transaction, the director owned 45,000 shares of the company’s stock, valued at approximately $213,750. The trade was a 28.57% increase in their position. The purchase was disclosed in a filing with the SEC, which can be accessed through this link. Also, Director David Horn purchased 10,000 shares of the firm’s stock in a transaction on Friday, August 14th. The stock was bought at an average price of $4.75 per share, with a total value of $47,500.00. Following the acquisition, the director owned 10,000 shares in the company, valued at $47,500. This trade represents a ∞ increase in their ownership of the stock. The disclosure for this purchase is available in the SEC filing. Insiders acquired a total of 116,000 shares of company stock worth $551,000 in the last ninety days. 10.10% of the stock is currently owned by company insiders.

About FocalTherics

EDAP TMS SA, together with its subsidiaries, develops, produces, markets, distributes, and maintains a portfolio of minimally invasive medical devices for the treatment of urological diseases in Asia, France, the United States, and internationally. It operates in three segments: High Intensity Focused Ultrasound (HIFU), Extracorporeal ShockWave Lithotripsy (ESWL), and Distribution Services (DIST). The HIFU segment develops, manufactures, and markets medical devices based on HIFU technology for the minimally invasive treatment of urological and other clinical indications.